Uncategorized-EN
Osteomyc
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma (Osteomyc) Agents: OMO-103 Phase II Status Open, recruiting Sponsor Vall d’Hebron Institute of Oncology This is an open-label, unicentric, single-arm Phase 2 pilot study to serve as a proof-of-concept…
Read MoreMETÁFORAS QUE IMPORTAN ¿Somos raros? ¿Somos guerreros?
El uso de metáforas está estrechamente relacionado con el cáncer: recurrimos a ellas porque la literalidad a veces es aterradora. Y porque, dentro de la zona de confort del lenguaje, podemos salvarnos (o condenarnos). Natalia Fernández, investigadora del lenguaje de los pacientes con sarcoma, analiza por qué recurrimos a las metáforas y aboga por humanizar nuestro lenguaje.
Read MoreEURACAN Launches New Website – Share Your Feedback!
🆕 EURACAN has recently launched its new website, designed to enhance accessibility and provide valuable resources for the sarcoma community. We invite you to explore the site and let us know your thoughts! 🌐 Visit the new EURACAN website HERE. To ensure the website meets the needs of its users, EURACAN is conducting a short…
Read MoreExciting News: FDA Approves Vimseltinib for TGCT!
The FDA has officially approved vimseltinib for the treatment of symptomatic tenosynovial giant cell tumor (TGCT), a rare, non-malignant tumor that affects joints, tendons, and the synovial lining. This condition can cause pain, swelling, and reduced mobility, significantly impacting patients’ quality of life. For those with inoperable or recurrent TGCT, vimseltinib offers an alternative to…
Read MoreWhy and How should I support SPAGN? Global networking is essential for progress in sarcoma care
The sadness about the death of her 34-year-old sister Paola and the frustration about the few options available for sarcoma patients, instilled – 17 years ago – the wish in Ornella Gonzato to do something to make sarcoma patients less ‘invisible’. In the wake of the forthcoming SPAGN annual conference, the longstanding Board member calls upon patients and patient advocates in getting active to support the global network for sarcoma patients. From her own experience she can tell why it makes a difference to others and oneself and gives tips about how to get started.
Read MoreSweden: Barncancerfonden – The Swedish Childhood Cancer Fund
Sweden: Barncancerfonden – The Swedish Childhood Cancer Fund Back to members Organisation Profile The Swedish Childhood Cancer Fund is dedicated to ensuring every child with cancer survives and lives a good life. They fund research aimed to develop more effective and milder treatments that are tough on cancer but gentle on children. Additionally,…
Read MoreSome metaphors that matter – Are we rare? Are we warriors?
The use of metaphors is closely connected with cancer: We turn to them because literalness is sometimes terrifying. And because, within the comfort zone of language, we can save (or condemn) ourselves. Natalia Fernández, researcher into language of sarcoma patients, analyses why we resort to metaphors and pleads for humanizing our language.
Read MoreUSA: The EHE Foundation
USA: The EHE Foundation Back to members Organisation Profile The EHE Foundation is the leading global nonprofit advocacy and research organization dedicated to finding treatments and a cure for epithelioid hemangioendothelioma (EHE), an ultra-rare vascular cancer. We unite patients, researchers, clinicians, and industry to drive scientific progress, advance research, and improve…
Read MoreUSA: Clear Cell Sarcoma Foundation
USA: Clear Cell Sarcoma Foundation Back to members Organisation Profile Mission statement: The Clear Cell Sarcoma Foundation (formerly Sara’s Cure) is a Charleston, SC based 501(c)(3) with one mission – to make Clear Cell Sarcoma survivable through education and scientific research while ensuring all patients and caregivers impacted have a voice and platform to enact…
Read MoreUSA: Make IT Better Agents – pediatric osteosarcoma nonprofit
USA: Make IT Better Agents – pediatric osteosarcoma nonprofit Back to members Organisation Profile MISSION: MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer.…
Read More